CHAMPIONS ONCOLOGY Business Summary

Champions Oncology, Inc. (CSBR) operates as a specialized contract research organization (CRO) and data-driven technology company focused on translational oncology. The company generates revenue through two primary business segments: Translational Oncology Solutions (TOS), which provides preclinical and clinical research services to pharmaceutical and biotechnology firms, and Personalized Oncology Solutions (POS), which assists physicians in developing individualized cancer treatment plans. Revenue is primarily derived from research service fees and high-margin data licensing of its proprietary Lumin platform, which leverages a massive bank of over 1,400 clinically annotated Patient-Derived Xenograft (PDX) models. In the competitive landscape, Champions Oncology contends with large-scale global CROs such as Charles River Laboratories, Crown Bioscience, and WuXi AppTec. It distinguishes itself by offering high-fidelity "mouse avatars" and multi-omic datasets that provide superior predictive accuracy for drug efficacy compared to traditional cell-line models. The company was founded in 2007 by Dr. David Sidransky, a renowned Johns Hopkins oncologist who currently serves as Lead Director. The leadership team is headed by Chief Executive Officer Rob Brainin, who took the helm in August 2025 following senior roles at Veracyte and Genuity Science. He is supported by Executive Chair Dr. Ronnie Morris, who transitioned from the CEO role after nearly a decade of leadership, and Chief Financial Officer David Miller, who oversees the firm's transition toward data-centric profitability. Other key executives include President Brady Davis and Chief Strategy & Innovation Officer Dr. Philip Breitfeld, formerly of IQVIA. The company maintains a high level of insider ownership, approximately 47%, with notable institutional backing from firms such as 180 Degree Capital and Pareto Ventures, reflecting strong management conviction in its Corellia AI discovery subsidiary and long-term data monetization strategy.